Erratum to: JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer
Authors:
Yi Fang Lee, Lance David Miller, Xiu Bin Chan, Michael A. Black, Brendan Pang, Chee Wee Ong, Manuel Salto-Tellez, Edison T. Liu, Kartiki V. Desai
Main text: After the publication of this work [1] an error was noticed in Fig. 8. In the SMAD2P465/467 panel, the images for MCF-7 and MDA MB 231 cells were accidentally duplicated. The corrected figure is shown below. We apologize for this error, which does not affect the findings or conclusions of the article.
Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.